Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 190

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Development and Independent Validation of a Prognostic Assay for Stage II Colon Cancer Using Formalin-Fixed Paraffin-Embedded Tissue

Kennedy, Richard D., Bylesjo, Max, Kerr, Peter, Davison, Timothy, Black, Julie M., Kay, Elaine W., Holt, Robert J., Proutski, Vitali, Ahdesmaki, Miika, Farztdinov, Vadim, Goffard, Nicolas, Hey, Peter, McDyer, Fionnuala, Mulligan, Karl, Mussen, Julie, O'Brien, Eamonn, Oliver, Gavin, Walker, Steven M., Mulligan, Jude M., Wilson, Claire, Winter, Andreas, O'Donoghue, Diarmuid, Mulcahy, Hugh, O'Sullivan, Jacintha, Sheahan, Kieran, Hyland, John, Dhir, Rajiv, Bathe, Oliver F., Winqvist, Ola, Manne, Upender, Shanmugam, Chandrakumar, Ramaswamy, Sridhar, Leon, Eduardo J., Smith, William I., McDermott, Ultan, Wilson, Richard H., Longley, Daniel, Marshall, John, Cummins, Robert, Sargent, Daniel J., Johnston, Patrick G., Harkin, D. Paul·2011·Journal of Clinical Oncology

Abstract

Purpose: Current prognostic factors are poor at identifying patients at risk of disease recurrence after surgery for stage II colon cancer. Here we describe a DNA microarray–based prognostic assay using clinically relevant formalin-fixed paraffin-embedded (FFPE) samples. Patients and Methods: A gene signature was developed from a balanced set of 73 patients with recurrent disease (high risk) and 142 patients with no recurrence (low risk) within 5 years of surgery. Results: The 634–probe set signature identified high-risk patients with a hazard ratio (HR) of 2.62 (P < .001) during cross validation of the training set. In an independent validation set of 144 samples, the signature identified high-risk patients with an HR of 2.53 (P < .001) for recurrence and an HR of 2.21 (P = .0084) for cancer-related death. Additionally, the signature was shown to perform independently from known prognostic factors (P < .001). Conclusion: This gene signature represents a novel prognostic biomarker for patients with stage II colon cancer that can be applied to FFPE tumor samples.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2011.35.4498

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 190

Metadata

Authors
Kennedy, R. D., Bylesjo, M., Kerr, P., Davison, T., Black, J. M., Kay, E. W., Holt, R. J., Proutski, V., Ahdesmaki, M., Farztdinov, V., Goffard, N., Hey, P., McDyer, F., Mulligan, K., Mussen, J., O'Brien, E., Oliver, G., Walker, S. M., Mulligan, J. M., Wilson, C., Winter, A., O'Donoghue, D., Mulcahy, H., O'Sullivan, J., Sheahan, K., Hyland, J., Dhir, R., Bathe, O. F., Winqvist, O., Manne, U., Shanmugam, C., Ramaswamy, S., Leon, E. J., Smith, W. I., McDermott, U., Wilson, R. H., Longley, D., Marshall, J., Cummins, R., Sargent, D. J., Johnston, P. G., & Harkin, D. P.
Venue
Journal of Clinical Oncology
Published
2011-12-10
Volume
29
Issue
35
Pages
4620-4626
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2170468505
Cited by
190
References
2
FWCI
6.11
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Development and Independent Validation of a Prognostic Assay for Stage II Colon Cancer Using Formalin-Fixed Paraffin-Embedded Tissue. https://app.cochat.ai/papers/10.1200/jco.2011.35.4498
The paper
Kennedy, R. D., Bylesjo, M., Kerr, P., Davison, T., Black, J. M., Kay, E. W., Holt, R. J., Proutski, V., Ahdesmaki, M., Farztdinov, V., Goffard, N., Hey, P., McDyer, F., Mulligan, K., Mussen, J., O'Brien, E., Oliver, G., Walker, S. M., Mulligan, J. M., . . . Harkin, D. P. (2011). Development and Independent Validation of a Prognostic Assay for Stage II Colon Cancer Using Formalin-Fixed Paraffin-Embedded Tissue. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2011.35.4498

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.